Publications

Found 3 results
Filters: Author is Q. Mao  [Clear All Filters]
2012
M. N. Chen, Wang, P., Zhang, J., Zhou, B. Y., Mao, Q., and Liu, Y. H., Analysis of the role of hMLH1 hypermethylation and microsatellite instability in meningioma progression, vol. 11, pp. 3933-3941, 2012.
Alvino E, Fernandez E and Pallini R (2000). Microsatellite instability in primary brain tumors. Neurol. Res. 22: 571-575. PMid:11045018   Baylin SB and Herman JG (2000). DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 16: 168-174. http://dx.doi.org/10.1016/S0168-9525(99)01971-X   Bello MJ, Aminoso C, Lopez-Marin I, Arjona D, et al. (2004). DNA methylation of multiple promoter-associated CpG islands in meningiomas: relationship with the allelic status at 1p and 22q. Acta Neuropathol. 108: 413-421. http://dx.doi.org/10.1007/s00401-004-0911-6 PMid:15365725   Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, et al. (1998). A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 58: 5248-5257. PMid:9823339   Cunningham JM, Christensen ER, Tester DJ, Kim CY, et al. (1998). Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res. 58: 3455-3460. PMid:9699680   Dams E, Van de Kelft EJ, Martin JJ, Verlooy J, et al. (1995). Instability of microsatellites in human gliomas. Cancer Res. 55: 1547-1549. PMid:7882363   Deng G, Chen A, Hong J, Chae HS, et al. (1999). Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression. Cancer Res. 59: 2029-2033. PMid:10232580   Dietmaier W, Wallinger S, Bocker T, Kullmann F, et al. (1997). Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression. Cancer Res. 57: 4749-4756. PMid:9354436   Dong SM, Pang JC, Poon WS, Hu J, et al. (2001). Concurrent hypermethylation of multiple genes is associated with grade of oligodendroglial tumors. J. Neuropathol. Exp. Neurol. 60: 808-816. PMid:11487055   Esteller M, Catasus L, Matias-Guiu X, Mutter GL, et al. (1999). hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis. Am. J. Pathol. 155: 1767-1772. http://dx.doi.org/10.1016/S0002-9440(10)65492-2   Fleisher AS, Esteller M, Tamura G, Rashid A, et al. (2001). Hypermethylation of the hMLH1 gene promoter is associated with microsatellite instability in early human gastric neoplasia. Oncogene 20: 329-335. http://dx.doi.org/10.1038/sj.onc.1204104 PMid:11313962   Herman JG, Umar A, Polyak K, Graff JR, et al. (1998). Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. U. S. A. 95: 6870-6875. http://dx.doi.org/10.1073/pnas.95.12.6870 PMid:9618505 PMCid:22665   Kulke MH, Thakore KS, Thomas G, Wang H, et al. (2001). Microsatellite instability and hMLH1/hMSH2 expression in Barrett esophagus-associated adenocarcinoma. Cancer 91: 1451-1457. http://dx.doi.org/10.1002/1097-0142(20010415)91:8<1451::AID-CNCR1152>3.0.CO;2-Z   Leung SY, Yuen ST, Chung LP, Chu KM, et al. (1999). hMLH1 promoter methylation and lack of hMLH1 expression in sporadic gastric carcinomas with high-frequency microsatellite instability. Cancer Res. 59: 159-164. PMid:9892201   Liu Y, Pang JC, Dong S, Mao B, et al. (2005). Aberrant CpG island hypermethylation profile is associated with atypical and anaplastic meningiomas. Hum. Pathol. 36: 416-425. http://dx.doi.org/10.1016/j.humpath.2005.02.006 PMid:15892004   Longstreth WT Jr, Dennis LK, McGuire VM, Drangsholt MT, et al. (1993). Epidemiology of intracranial meningioma. Cancer 72: 639-648. http://dx.doi.org/10.1002/1097-0142(19930801)72:3<639::AID-CNCR2820720304>3.0.CO;2-P   Lundin DA, Blank A, Berger MS and Silber JR (1998). Microsatellite instability is infrequent in sporadic adult gliomas. Oncol. Res. 10: 421-428. PMid:10100759   Ng HK, Lau KM, Tse JY, Lo KW, et al. (1995). Combined molecular genetic studies of chromosome 22q and the neurofibromatosis type 2 gene in central nervous system tumors. Neurosurgery 37: 764-773. http://dx.doi.org/10.1227/00006123-199510000-00022 PMid:8559307   Perry A, Stafford SL, Scheithauer BW, Suman VJ, et al. (1997). Meningioma grading: an analysis of histologic parameters. Am. J. Surg. Pathol. 21: 1455-1465. http://dx.doi.org/10.1097/00000478-199712000-00008 PMid:9414189   Perry A, Scheithauer BW, Stafford SL, Lohse CM, et al. (1999). "Malignancy" in meningiomas: a clinicopathologic study of 116 patients, with grading implications. Cancer 85: 2046-2056. http://dx.doi.org/10.1002/(SICI)1097-0142(19990501)85:9<2046::AID-CNCR23>3.0.CO;2-M   Perry A, Giannini C, Raghavan R, Scheithauer BW, et al. (2001). Aggressive phenotypic and genotypic features in pediatric and NF2-associated meningiomas: a clinicopathologic study of 53 cases. J. Neuropathol. Exp. Neurol. 60: 994-1003. PMid:11589430   Pykett MJ, Murphy M, Harnish PR and George DL (1994). Identification of a microsatellite instability phenotype in meningiomas. Cancer Res. 54: 6340-6343. PMid:7987826   Radner H, Blumcke I, Reifenberger G and Wiestler OD (2002). The new WHO classification of tumors of the nervous system 2000. Pathology and genetics. Pathologe 23: 260-283. http://dx.doi.org/10.1007/s00292-002-0530-8 PMid:12185780   Salvesen HB, MacDonald N, Ryan A, Iversen OE, et al. (2000). Methylation of hMLH1 in a population-based series of endometrial carcinomas. Clin. Cancer Res. 6: 3607-3613. PMid:10999752   Sambrook J, Fritsh EF and Maniatis T (1989). Molecular Cloning: A Laboratory Manual. 2nd edn. Cold Spring Harbor Laboratory Press, New York.   Simpkins SB, Bocker T, Swisher EM, Mutch DG, et al. (1999). MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers. Hum. Mol. Genet. 8: 661-666. http://dx.doi.org/10.1093/hmg/8.4.661 PMid:10072435   Skotheim RI, Diep CB, Kraggerud SM, Jakobsen KS, et al. (2001). Evaluation of loss of heterozygosity/allelic imbalance scoring in tumor DNA. Cancer Genet. Cytogenet. 127: 64-70. http://dx.doi.org/10.1016/S0165-4608(00)00433-7   Sobrido MJ, Pereira CR, Barros F, Forteza J, et al. (2000). Low frequency of replication errors in primary nervous system tumours. J. Neurol. Neurosurg. Psychiatry 69: 369-375. http://dx.doi.org/10.1136/jnnp.69.3.369 PMid:10945812 PMCid:1737093   Thibodeau SN, Bren G and Schaid D (1993). Microsatellite instability in cancer of the proximal colon. Science 260: 816- 819. http://dx.doi.org/10.1126/science.8484122 PMid:8484122   Ueki K, Wen-Bin C, Narita Y, Asai A, et al. (1999). Tight association of loss of merlin expression with loss of heterozygosity at chromosome 22q in sporadic meningiomas. Cancer Res. 59: 5995-5998. PMid:10606247   Veigl ML, Kasturi L, Olechnowicz J, Ma AH, et al. (1998). Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc. Natl. Acad. Sci. U. S. A. 95: 8698-8702. http://dx.doi.org/10.1073/pnas.95.15.8698 PMid:9671741 PMCid:21139   Wellenreuther R, Kraus JA, Lenartz D, Menon AG, et al. (1995). Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma. Am. J. Pathol. 146: 827-832. PMid:7717450 PMCid:1869258   Wirtz HC, Müller W, Noguchi T, Scheven M, et al. (1998). Prognostic value and clinicopathological profile of microsatellite instability in gastric cancer. Clin. Cancer Res. 4: 1749-1754. PMid:9676851   Zhu J, Guo SZ, Beggs AH, Maruyama T, et al. (1996). Microsatellite instability analysis of primary human brain tumors. Oncogene 12: 1417-1423. PMid:8622857
J. N. Zhang, Yi, S. H., Zhang, X. H., Liu, X. Y., Mao, Q., Li, S. Q., Xiong, W. H., Qiu, Y. M., Chen, T., and Ge, J. W., Association of p53 Arg72Pro and MDM2 SNP309 polymorphisms with glioma, vol. 11, pp. 3618-3628, 2012.
Bai J, Dai J, Yu H, Shen H, et al. (2009). Cigarette smoking, MDM2 SNP309, gene-environment interactions, and lung cancer risk: a meta-analysis. J. Toxicol. Environ. Health A 72: 677-682. http://dx.doi.org/10.1080/15287390902840930 PMid:19492228   Begg CB and Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101. http://dx.doi.org/10.2307/2533446 PMid:7786990   Biernat W, Kleihues P, Yonekawa Y and Ohgaki H (1997). Amplification and overexpression of MDM2 in primary (de novo) glioblastomas. J. Neuropathol. Exp. Neurol. 56: 180-185. http://dx.doi.org/10.1097/00005072-199702000-00009 PMid:9034372   Bond GL, Hu W, Bond EE, Robins H, et al. (2004). A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119: 591-602. http://dx.doi.org/10.1016/j.cell.2004.11.022 PMid:15550242   Bredel M, Scholtens DM, Yadav AK, Alvarez AA, et al. (2011). NFKBIA deletion in glioblastomas. N. Engl. J. Med. 364: 627-637. http://dx.doi.org/10.1056/NEJMoa1006312 PMid:21175304   Dai S, Mao C, Jiang L, Wang G, et al. (2009). P53 polymorphism and lung cancer susceptibility: a pooled analysis of 32 case-control studies. Hum. Genet. 125: 633-638. http://dx.doi.org/10.1007/s00439-009-0664-3 PMid:19357867   DerSimonian R and Laird N (1986). Meta-analysis in clinical trials. Control Clin. Trials 7: 177-188. http://dx.doi.org/10.1016/0197-2456(86)90046-2   Dumont P, Leu JI, Della Pietra AC, George DL, et al. (2003). The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet. 33: 357-365. http://dx.doi.org/10.1038/ng1093 PMid:12567188   Egger M, Davey SG, Schneider M and Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634. http://dx.doi.org/10.1136/bmj.315.7109.629 PMid:9310563 PMCid:2127453   El Hallani S, Marie Y, Idbaih A, Rodero M, et al. (2007). No association of MDM2 SNP309 with risk of glioblastoma and prognosis. J. Neurooncol. 85: 241-244. http://dx.doi.org/10.1007/s11060-007-9416-1 PMid:17568997   El Hallani S, Ducray F, Idbaih A, Marie Y, et al. (2009). TP53 codon 72 polymorphism is associated with age at onset of glioblastoma. Neurology 72: 332-336. http://dx.doi.org/10.1212/01.wnl.0000341277.74885.ec PMid:19171829   Fang F, Yu XJ, Yu L and Yao L (2011). MDM2 309 T/G polymorphism is associated with colorectal cancer risk especially in Asians: a meta-analysis. Med. Oncol. 28: 981-985. http://dx.doi.org/10.1007/s12032-010-9577-1 PMid:20503107   Gu J, Liu Y, Kyritsis AP and Bondy ML (2009). Molecular epidemiology of primary brain tumors. Neurotherapeutics 6: 427-435. http://dx.doi.org/10.1016/j.nurt.2009.05.001 PMid:19560733   Haupt Y, Maya R, Kazaz A and Oren M (1997). Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299. http://dx.doi.org/10.1038/387296a0 PMid:9153395   Hunter SB, Abbott K, Varma VA, Olson JJ, et al. (1995). Reliability of differential PCR for the detection of EGFR and MDM2 gene amplification in DNA extracted from FFPE glioma tissue. J. Neuropathol. Exp. Neurol. 54: 57-64. http://dx.doi.org/10.1097/00005072-199501000-00007 PMid:7815080   Idbaih A, Boisselier B, Marie Y, Sanson M, et al. (2008). Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors. Brain Res. 1198: 16-20. http://dx.doi.org/10.1016/j.brainres.2008.01.027 PMid:18262501   Jeong BS, Hu W, Belyi V, Rabadan R, et al. (2010). Differential levels of transcription of p53-regulated genes by the arginine/proline polymorphism: p53 with arginine at codon 72 favors apoptosis. FASEB J. 24: 1347-1353. http://dx.doi.org/10.1096/fj.09-146001 PMid:20019240   Jha P, Jha P, Pathak P, Chosdol K, et al. (2011). TP53 polymorphisms in gliomas from Indian patients: Study of codon 72 genotype, rs1642785, rs1800370 and 16 base pair insertion in intron-3. Exp. Mol. Pathol. 90: 167-172. http://dx.doi.org/10.1016/j.yexmp.2010.11.002 PMid:21115003   Khatri RG, Navaratne K and Weil RJ (2008). The role of a single nucleotide polymorphism of MDM2 in glioblastoma multiforme. J. Neurosurg. 109: 842-848. http://dx.doi.org/10.3171/JNS/2008/109/11/0842 PMid:18976073   Kubbutat MH, Jones SN and Vousden KH (1997). Regulation of p53 stability by Mdm2. Nature 387: 299-303. http://dx.doi.org/10.1038/387299a0 PMid:9153396   Kussie PH, Gorina S, Marechal V, Elenbaas B, et al. (1996). Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274: 948-953. http://dx.doi.org/10.1126/science.274.5289.948 PMid:8875929   Lima-Ramos V, Pacheco-Figueiredo L, Costa S, Pardal F, et al. (2008). TP53 codon 72 polymorphism in susceptibility, overall survival, and adjuvant therapy response of gliomas. Cancer Genet. Cytogenet. 180: 14-19. http://dx.doi.org/10.1016/j.cancergencyto.2007.08.019 PMid:18068527   Liu L, Wang K, Zhu ZM and Shao JH (2011). Associations between P53 Arg72Pro and development of digestive tract cancers: a meta-analysis. Arch. Med. Res. 42: 60-69. http://dx.doi.org/10.1016/j.arcmed.2011.01.008 PMid:21376265   Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, et al. (2007). The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114: 97-109. http://dx.doi.org/10.1007/s00401-007-0243-4 PMid:17618441 PMCid:1929165   Malmer B, Feychting M, Lonn S, Ahlbom A, et al. (2005). p53 Genotypes and risk of glioma and meningioma. Cancer Epidemiol. Biomarkers Prev. 14: 2220-2223. http://dx.doi.org/10.1158/1055-9965.EPI-05-0234 PMid:16172235   Malmer BS, Feychting M, Lonn S, Lindstrom S, et al. (2007). Genetic variation in p53 and ATM haplotypes and risk of glioma and meningioma. J. Neurooncol. 82: 229-237. http://dx.doi.org/10.1007/s11060-006-9275-1 PMid:17151932   Marin MC, Jost CA, Brooks LA, Irwin MS, et al. (2000). A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat. Genet. 25: 47-54. http://dx.doi.org/10.1038/75586 PMid:10802655   Minelli C, Thompson JR, Abrams KR, Thakkinstian A, et al. (2008). How should we use information about HWE in the meta-analyses of genetic association studies? Int. J. Epidemiol. 37: 136-146. http://dx.doi.org/10.1093/ije/dym234 PMid:18037675   Ohgaki H, Dessen P, Jourde B, Horstmann S, et al. (2004). Genetic pathways to glioblastoma: a population-based study. Cancer Res. 64: 6892-6899. http://dx.doi.org/10.1158/0008-5472.CAN-04-1337 PMid:15466178   Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, et al. (1993). Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362: 857-860. http://dx.doi.org/10.1038/362857a0 PMid:8479525   Parhar P, Ezer R, Shao Y, Allen JC, et al. (2005). Possible association of p53 codon 72 polymorphism with susceptibility to adult and pediatric high-grade astrocytomas. Brain Res. Mol. Brain Res. 137: 98-103. http://dx.doi.org/10.1016/j.molbrainres.2005.02.016 PMid:15950766   Pinto GR, Yoshioka FK, Silva RL, Clara CA, et al. (2008). Prognostic value of TP53 Pro47Ser and Arg72Pro single nucleotide polymorphisms and the susceptibility to gliomas in individuals from Southeast Brazil. Genet. Mol. Res. 7: 207-216. http://dx.doi.org/10.4238/vol7-1gmr415 PMid:18393224   Rajaraman P, Wang SS, Rothman N, Brown MM, et al. (2007). Polymorphisms in apoptosis and cell cycle control genes and risk of brain tumors in adults. Cancer Epidemiol. Biomarkers Prev. 16: 1655-1661. http://dx.doi.org/10.1158/1055-9965.EPI-07-0314 PMid:17684142   Shete S, Hosking FJ, Robertson LB, Dobbins SE, et al. (2009). Genome-wide association study identifies five susceptibility loci for glioma. Nat. Genet. 41: 899-904. http://dx.doi.org/10.1038/ng.407 PMid:19578367   Suzuki SO and Iwaki T (2000). Amplification and overexpression of mdm2 gene in ependymomas. Mod. Pathol. 13: 548-553. http://dx.doi.org/10.1038/modpathol.3880095 PMid:10824927   Tsuiki H, Nishi T, Takeshima H, Yano S, et al. (2007). Single nucleotide polymorphism 309 affects murin-double-minute 2 protein expression but not glioma tumorigenesis. Neurol. Med. Chir. 47: 203-208. http://dx.doi.org/10.2176/nmc.47.203   Wang LE, Bondy ML, Shen H, El-Zein R, et al. (2004). Polymorphisms of DNA repair genes and risk of glioma. Cancer Res. 64: 5560-5563. http://dx.doi.org/10.1158/0008-5472.CAN-03-2181 PMid:15313891   Wrensch M, Fisher JL, Schwartzbaum JA, Bondy M, et al. (2005). The molecular epidemiology of gliomas in adults. Neurosurg. Focus 19: E5. http://dx.doi.org/10.3171/foc.2005.19.5.6 PMid:16398469   Wrensch M, Jenkins RB, Chang JS, Yeh RF, et al. (2009). Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat. Genet. 41: 905-908. http://dx.doi.org/10.1038/ng.408 PMid:19578366 PMCid:2923561   Yang M, Guo Y, Zhang X, Miao X, et al. (2007). Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer. Carcinogenesis 28: 1996-2001. http://dx.doi.org/10.1093/carcin/bgm168 PMid:17638920   Zhou Y, Li N, Zhuang W, Liu GJ, et al. (2007). P53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Int. J. Cancer 121: 1481-1486. http://dx.doi.org/10.1002/ijc.22833 PMid:17546594
2011
P. Wang, Ni, R. Y., Chen, M. N., Mou, K. J., Mao, Q., and Liu, Y. H., Expression of aquaporin-4 in human supratentorial meningiomas with peritumoral brain edema and correlation of VEGF with edema formation, vol. 10, pp. 2165-2171, 2011.
Bitzer M, Wockel L, Morgalla M, Keller C, et al. (1997a). Peritumoural brain oedema in intracranial meningiomas: influence of tumour size, location and histology. Acta Neurochir. 139: 1136-1142. http://dx.doi.org/10.1007/BF01410973 PMid:9479419 Bitzer M, Wockel L, Luft AR, Wakhloo AK, et al. (1997b). The importance of pial blood supply to the development of peritumoral brain edema in meningiomas. J. Neurosurg. 87: 368-373. http://dx.doi.org/10.3171/jns.1997.87.3.0368 PMid:9285600 Bitzer M, Opitz H, Popp J, Morgalla M, et al. (1998). Angiogenesis and brain oedema in intracranial meningiomas: influence of vascular endothelial growth factor. Acta Neurochir. 140: 333-340. http://dx.doi.org/10.1007/s007010050106 PMid:9689324 Campbell BA, Jhamb A, Maguire JA, Toyota B, et al. (2009). Meningiomas in 2009: controversies and future challenges. Am. J. Clin. Oncol. 32: 73-85. http://dx.doi.org/10.1097/COC.0b013e31816fc920 PMid:19194129 Ding YS, Wang HD, Tang K, Hu ZG, et al. (2008). Expression of vascular endothelial growth factor in human meningiomas and peritumoral brain areas. Ann. Clin. Lab. Sci. 38: 344-351. PMid:18988927 Goldman CK, Bharara S, Palmer CA, Vitek J, et al. (1997). Brain edema in meningiomas is associated with increased vascular endothelial growth factor expression. Neurosurgery 40: 1269-1277. http://dx.doi.org/10.1097/00006123-199706000-00029 PMid:9179901 Ide M, Jimbo M, Kubo O, Yamamoto M, et al. (1992). Peritumoral brain edema associated with meningioma-histological study of the tumor margin and surrounding brain. Neurol. Med. Chir. 32: 65-71. http://dx.doi.org/10.2176/nmc.32.65 PMid:1376862 Jung JS, Bhat RV, Preston GM, Guggino WB, et al. (1994). Molecular characterization of an aquaporin cDNA from brain: candidate osmoreceptor and regulator of water balance. Proc. Natl. Acad. Sci. U. S. A. 91: 13052-13056. http://dx.doi.org/10.1073/pnas.91.26.13052 Kalkanis SN, Carroll RS, Zhang J, Zamani AA, et al. (1996). Correlation of vascular endothelial growth factor messenger RNA expression with peritumoral vasogenic cerebral edema in meningiomas. J. Neurosurg. 85: 1095-1101. http://dx.doi.org/10.3171/jns.1996.85.6.1095 PMid:8929501 Klatzo I (1994). Evolution of brain edema concepts. Acta Neurochir. Suppl. 60: 3-6. Machein MR and Plate KH (2000). VEGF in brain tumors. J. Neurooncol. 50: 109-120. http://dx.doi.org/10.1023/A:1006416003964 PMid:11245271 Ng WH, Hy JW, Tan WL, Liew D, et al. (2009). Aquaporin-4 expression is increased in edematous meningiomas. J. Clin. Neurosci. 16: 441-443. http://dx.doi.org/10.1016/j.jocn.2008.04.028 PMid:19153045 Otsuka S, Tamiya T, Ono Y, Michiue H, et al. (2004). The relationship between peritumoral brain edema and the expression of vascular endothelial growth factor and its receptors in intracranial meningiomas. J. Neurooncol. 70: 349-357. http://dx.doi.org/10.1007/s11060-004-9164-4 PMid:15662977 Provias J, Claffey K, delAguila L, Lau N, et al. (1997). Meningiomas: role of vascular endothelial growth factor/vascular permeability factor in angiogenesis and peritumoral edema. Neurosurgery 40: 1016-1026. http://dx.doi.org/10.1097/00006123-199705000-00027 PMid:9149260 Saadoun S, Papadopoulos MC, Davies DC, Krishna S, et al. (2002). Aquaporin-4 expression is increased in oedematous human brain tumours. J. Neurol. Neurosurg. Psychiatry 72: 262-265. http://dx.doi.org/10.1136/jnnp.72.2.262 PMid:50411 Tait MJ, Saadoun S, Bell BA and Papadopoulos MC (2008). Water movements in the brain: role of aquaporins. Trends Neurosci. 31: 37-43. http://dx.doi.org/10.1016/j.tins.2007.11.003 PMid:18054802 Yoshioka H, Hama S, Taniguchi E, Sugiyama K, et al. (1999). Peritumoral brain edema associated with meningioma: influence of vascular endothelial growth factor expression and vascular blood supply. Cancer 85: 936-944. http://dx.doi.org/10.1002/(SICI)1097-0142(19990215)85:4<936::AID-CNCR23>3.0.CO;2-J